SeaStar Medical Holding Management

Management Kriterienprüfungen 3/4

SeaStar Medical Holding CEO ist Eric Schlorff , ernannt in Jul 2019, hat eine Amtszeit von 5.33 Jahren. Die jährliche Gesamtvergütung beträgt $637.96K , bestehend aus 65.8% Gehalt und 34.2% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 1.12% der Aktien des Unternehmens, im Wert von $115.01K . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 2.3 Jahre bzw. 0.9 Jahre.

Wichtige Informationen

Eric Schlorff

Geschäftsführender

US$638.0k

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	65.8%
Amtszeit als Geschäftsführer	5.3yrs
Eigentum des Geschäftsführers	1.1%
Durchschnittliche Amtszeit des Managements	2.3yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	less than a year

Jüngste Management Updates

Recent updates

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Eric Schlorff im Vergleich zu den Einnahmen von SeaStar Medical Holding verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Sep 30 2024	n/a	n/a	-US$30m
Jun 30 2024	n/a	n/a	-US$33m
Mar 31 2024	n/a	n/a	-US$32m
Dec 31 2023	US$638k	US$420k	-US$26m
Sep 30 2023	n/a	n/a	-US$25m
Jun 30 2023	n/a	n/a	-US$20m
Mar 31 2023	n/a	n/a	-US$18m
Dec 31 2022	US$2m	US$320k	-US$12m
Sep 30 2022	n/a	n/a	-US$5m
Jun 30 2022	n/a	n/a	-US$4m
Mar 31 2022	n/a	n/a	-US$5m
Dec 31 2021	US$323k	US$300k	-US$5m

Vergütung im Vergleich zum Markt: EricDie Gesamtvergütung ($USD637.96K) liegt im Durchschnitt der Unternehmen ähnlicher Größe auf dem Markt US ($USD647.72K).

Entschädigung vs. Einkommen: EricDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Eric Schlorff (51 yo)

5.3yrs

Amtszeit

US$637,960

Vergütung

Mr. Eric Schlorff serves as Chief Executive Officer and Executive Director of SeaStar Medical Holding Corporation since July 2019 and serves as its President. He served as Chief Operating Officer at LMF Ac...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Eric Schlorff	CEO, President & Executive Director	5.3yrs	US$637.96k	1.12% $ 115.0k
Kevin Chung	Chief Medical Officer	2.3yrs	US$495.31k	0.31% $ 32.2k
H. Humes	Co-Founder and Managing Director	29.8yrs	US$205.93k	keine Daten
David Green	Chief Financial Officer	less than a year	keine Daten	0.24% $ 24.3k
Tom Mullen	Vice President of Operations & Product Development	2.8yrs	keine Daten	keine Daten
Tim Varacek	Senior VP of Commercial & Business Operations	less than a year	keine Daten	keine Daten
Sai Iyer	Senior Vice President of Medical Affairs & Research	less than a year	keine Daten	keine Daten

2.3yrs

Durchschnittliche Betriebszugehörigkeit

51yo

Durchschnittliches Alter

Erfahrenes Management: ICUDas Führungsteam des Unternehmens gilt als erfahren (2.3 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Eric Schlorff	CEO, President & Executive Director	5.3yrs	US$637.96k	1.12% $ 115.0k
Glenn Chertow	Member of Medical Advisory Board	no data	keine Daten	keine Daten
Ravindra Mehta	Member of Medical Advisory Board	no data	keine Daten	keine Daten
Kenneth Van Heel	Independent Director	3.8yrs	US$88.16k	0.055% $ 5.6k
Richard Barnett	Independent Chairman	3.8yrs	US$126.16k	0.079% $ 8.2k
Allan Collins	Independent Director	3.8yrs	US$80.16k	0.050% $ 5.1k
David Askenazi	Member of Scientific Advisory Board	less than a year	keine Daten	keine Daten
Ayse Akcan-Arikan	Member of Scientific Advisory Board	less than a year	keine Daten	keine Daten
Sean Bagshaw	Member of Scientific Advisory Board	less than a year	keine Daten	keine Daten
Rajit Basu	Member of Scientific Advisory Board	less than a year	keine Daten	keine Daten
Andriy Batchinsky	Member of Scientific Advisory Board	less than a year	keine Daten	keine Daten
John Neuman	Director	less than a year	keine Daten	keine Daten

0.9yrs

Durchschnittliche Betriebszugehörigkeit

60yo

Durchschnittliches Alter

Erfahrener Vorstand: ICUDie Vorstandsmitglieder gelten nicht als erfahren ( 0.9 Jahre durchschnittliche Amtszeit), was auf einen neuen Vorstand hindeutet.

SeaStar Medical Holding Management

Management Kriterienprüfungen 3/4

Wichtige Informationen

Jüngste Management Updates

High number of new and inexperienced directors

SeaStar Medical Holding Corporation Announces Board Changes

SeaStar Medical Holding Corporation Approves Class II Director Appointments

SeaStar Medical Holding Corporation, Annual General Meeting, Jun 04, 2024

SeaStar Medical Holding Corporation Announces Chief Financial Officer Changes

SeaStar Medical Forms Scientific Advisory Board of Pediatric and Adult Clinical Experts

Recent updates

FDA Grants Breakthrough Device Designation for Seastar Medical’S Selective Cytopheretic Device for Adults Undergoing Chronic Dialysis

SeaStar Medical Holding Corporation Announces Record Monthly Enrollment Achieve in It's Pivotal Adult AKI Trial

Seastar Medical Holding Corporation Enters into Confidential Settlement Agreement and Release with Nuwellis

Seastar Medical Holding Corporation Announces Enrollment in Its Adult Acute Kidney Injury Pivotal Trial Has Exceeded the Halfway Point Toward an Interim Analysis

SeaStar Medical Holding Corporation has filed a Follow-on Equity Offering in the amount of $25 million.

Levi & Korsinsky, LLP Notifies Investors in Seastar Medical Holding Corporation of A Class Action Securities Lawsuit

SeaStar Medical Holding Corporation Announces First Pediatric Patient Treated in A Commercial Setting with FDA-Approved QUELIMMUNE Therapeutic Device

SeaStar Medical Holding Corporation has completed a Follow-on Equity Offering in the amount of $10.000007 million.

SeaStar Medical Holding Corporation has filed a Follow-on Equity Offering in the amount of $10.000007 million.

SeaStar Medical Holding Corporation has filed a Follow-on Equity Offering in the amount of $10.000007 million.

The Schall Law Firm Reminds Class Action Lawsuit Against SeaStar Medical Holding Corporation

SeaStar Medical Holding Provides Notice to the Nasdaq Stock Market Regarding its Possible Violation of Nasdaq Listing Rule 5635(d)(2)

SeaStar Medical Holding Provides Notice to the Nasdaq Stock Market Regarding its Possible Violation of Nasdaq Listing Rule 5635(d)(2)

SeaStar Medical Holding Corporation Finalizes FDA Labeling Requirement for QUELIMMUNE, Paving the Way for First Commercial Sales as Humanitarian Use Device

High number of new and inexperienced directors

SeaStar Medical Holding Announces Compliance Update with Nasdaq Listing Rule 5550(b)(2) and Nasdaq Listing Rule 5550(a)(2)

SeaStar Medical Holding Corporation Announces Board Changes

SeaStar Medical Holding Corporation Approves Class II Director Appointments

SeaStar Medical Holding Corporation, Annual General Meeting, Jun 04, 2024

SeaStar Medical Announces $3.6 Million NIH Grant Award to Study the Selective Cytopheretic Device in Adult Patients with Severe Chronic Heart Failure

SeaStar Medical Announces $3.6 Million NIH Grant Award to Study the Selective Cytopheretic Device in Adult Patients with Severe Chronic Heart Failure

SeaStar Medical Holding Corporation announced delayed annual 10-K filing

Seastar Medical Provides Updates on Enrollment of Adult Pivotal Clinical Study and Commercial Launch of Quelimmune, FDA-Approved in Pediatric Patients

FDA Grants Humanitarian Device Exemption Approval to Seastar Medical’S Selective Cytopheretic Device for Pediatric Acute Kidney Injury

SeaStar Medical Holding Receives Notification from the Nasdaq Listing Qualifications Department Regarding the Company Regains Compliance with the Market Value Rule

SeaStar Medical Holding Corporation has filed a Follow-on Equity Offering in the amount of $9 million.

SeaStar Medical Holding Corporation has filed a Follow-on Equity Offering in the amount of $9 million.

SeaStar Medical Holding Corporation has filed a Follow-on Equity Offering in the amount of $9 million.

SeaStar Medical Holding Corporation Announces Chief Financial Officer Changes

SeaStar Medical Holding Receives Non-Compliance Notice from Nasdaq

SeaStar Medical Holding Corporation Updates Subject Enrollment in its Pivotal Trial with the Selective Cytopheretic Device in Adults with Acute Kidney Injury

SeaStar Medical Holding Corporation Updates Subject Enrollment in its Pivotal Trial with the Selective Cytopheretic Device in Adults with Acute Kidney Injury

SeaStar Medical Holding Receives Notification from the Nasdaq Listing Qualifications Department of the Nasdaq Stock Market

SeaStar Medical Forms Scientific Advisory Board of Pediatric and Adult Clinical Experts

New major risk - Shareholder dilution

U.S. Food and Drug Administration Issues Approvable Letter for SeaStar Medical Holding Corporation's Selective Cytopheretic Device for Pediatric Patients

FDA Grants SeaStar Medical’s Selective Cytopheretic Device Breakthrough Device Designation for Hepatorenal Syndrome

SeaStar Medical Holding Corporation Announces Publication of Case Series of Three Critically Ill Children with Acute Kidney Injury Safely Treated with it's Selective Cytopheretic Device

SeaStar Medical Holding Corporation Enrolls First Patient in NEUTRALIZE-AKI Pivotal Clinical Trial with the Selective Cytopheretic Device in Adults with Acute Kidney Injury

Seastar Medical Holding Receives Nasdaq Staff Deficiency Letter Regarding Non-Compliance with Market Value of Listed Securities Requirements

SeaStar Medical Holding Corporation, Annual General Meeting, Jun 28, 2023

SeaStar Medical Holding Corporation Provides Regulatory Update Related to HDE Application for Pediatric Selective Cytopheretic Device

SeaStar Medical Announces Details of the Selective Cytopheretic Device Pivotal Study in Critically ill Adults with Acute Kidney Injury

Seastar Medical Receives FDA Approval to Begin Study with Selective Cytopheretic Device to Reduce Hyperinflammation in Adults with Acute Kidney Injury

SeaStar Medical Holding Corporation Submits Investigational Device Exemption Application to FDA to Study a Novel Therapy to Reduce Hyperinflammation in Adult Acute Kidney Injury Patients

High number of new directors

Seastar Medical Appoints Rick Barnett as Chairman of the Board of Directors

No independent directors

SeaStar Medical Announces Positive Interim Safety Findings from Ongoing Study Evaluating the Selective Cytopheretic Device (SCD) in Children

Analyse der Geschäftsführervergütung

Geschäftsführer

Amtszeit

Vergütung

Führungsteam

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter